Adamas Pharmaceuticals Inc (ADMS) Stock Analyst Ratings
NASDAQ:ADMS - Nasdaq - Common Stock
ChartMill assigns a Buy % Consensus number of 71% to ADMS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 8.69. This target is 5.72% above the current price.
ADMS was analyzed by 14 analysts. The buy percentage consensus is at 71. So analysts seem to be have mildly positive about ADMS.
In the previous month the buy percentage consensus was at a similar level.
ADMS was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2021-11-17 | Northland Capital Markets | Downgrade | Outperform -> Market Perform |
| 2021-10-12 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2021-10-12 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2021-10-12 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2021-10-11 | William Blair | Downgrade | Outperform -> Market Perform |
| 2021-06-07 | HC Wainwright & Co. | Maintains | Buy |